The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1463
ISSUE1463
March 2, 2015
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
March 2, 2015 (Issue: 1463)
The FDA has approved ceftolozane/tazobactam
(Zerbaxa – Cubist), a combination of a new cephalosporin
antibiotic and a beta-lactamase inhibitor, for
intravenous treatment of complicated urinary tract
and intra-abdominal infections in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.